Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFENDER
NCT05757557Phase 2Completed
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitric oxide in acute kidney injury (AKI) (2 arms), sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoint: Incidence of Acute Kidney Injury at 7 days. Started Feb 2023; status: completed.
02
Drugs
nitric oxide
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05757557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757557.